Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
Personalized therapies are required for Fabry disease due to its large phenotypic spectrum and numerous different genotypes. In principle, missense mutations that do not affect the active site could be rescued with pharmacological chaperones. At present pharmacological chaperones for Fabry disease b...
Saved in:
| Main Authors: | Valentina Citro, Jorge Peña-García, Helena den-Haan, Horacio Pérez-Sánchez, Rosita Del Prete, Ludovica Liguori, Chiara Cimmaruta, Jan Lukas, Maria Vittoria Cubellis, Giuseppina Andreotti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0165463&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease
by: Jolanda M.P. Liefhebber, et al.
Published: (2024-12-01) -
Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
by: Giuseppina Andreotti, et al.
Published: (2015-01-01) -
Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function
by: Thomas Dal Maso, et al.
Published: (2025-05-01) -
Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy
by: Wanida Ruangsiriluk, et al.
Published: (2025-02-01) -
Impairment of chaperone‐mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis
by: Gennaro Napolitano, et al.
Published: (2015-01-01)